WO2006047625A2 - Method to promote wound healing - Google Patents

Method to promote wound healing Download PDF

Info

Publication number
WO2006047625A2
WO2006047625A2 PCT/US2005/038646 US2005038646W WO2006047625A2 WO 2006047625 A2 WO2006047625 A2 WO 2006047625A2 US 2005038646 W US2005038646 W US 2005038646W WO 2006047625 A2 WO2006047625 A2 WO 2006047625A2
Authority
WO
WIPO (PCT)
Prior art keywords
substance
wound
mammal
administered
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/038646
Other languages
English (en)
French (fr)
Other versions
WO2006047625A3 (en
Inventor
Mark L. Witten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immuneregen Biosciences Inc
Original Assignee
Immuneregen Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuneregen Biosciences Inc filed Critical Immuneregen Biosciences Inc
Priority to EP05813067A priority Critical patent/EP1809313A4/en
Priority to AU2005299341A priority patent/AU2005299341A1/en
Priority to US11/666,474 priority patent/US20080318869A1/en
Priority to JP2007539081A priority patent/JP2008518020A/ja
Priority to CA002585265A priority patent/CA2585265A1/en
Publication of WO2006047625A2 publication Critical patent/WO2006047625A2/en
Publication of WO2006047625A3 publication Critical patent/WO2006047625A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to the field of wound healing.
  • it relates to treatment of wounds inflicted by disease, surgery, injury, etc. More particularly it relates to treatment of wounds in irradiated individuals.
  • the wound healing process is adversely effected by irradiation. Irradiation causes a delay in the overall process. The early phase inflammatory response is inhibited. The formation and maturation of granulation tissue is retarded. And the reepithelialization process is delayed. These result in an overall prolongation of healing time Gu et al., J Environ Pathol Toxicol Oncol. 1998; 17:117-23. Particular components of the wound healing process that are affected include infiltrating macrophages and neutrophils, blood vessels, fibroblasts, collagen synthesis and secretion. Ibid.
  • a method for stimulating wound healing in a radiation-exposed mammal An effective amount of Substance P or an analog thereof is administered to a mammal that has been exposed to radiation and that has a wound.
  • the analog is selected from the group consisting of [Met-OH 11 ]- substance P, [Met-OMe 1 ⁇ -substance P, [Nle"]-substance P, [Pro 9 ]-substance P, [Sar 9 ]-substance P, [Tyr 8 ]-substance P, [p-Cl-Phe 7 ' 8 ] -substance P, [Sar 9 ,Met (O 2 ) H ]- substance P, and analogs having the amino acid backbone RPKPQQFFGLM-NH 2 .
  • Healing of the wound is stimulated.
  • Figure 1 shows the tail with bite wounds of a mouse that was subjected to irradiation.
  • Figure 2 shows the tail that had bite wounds of a mouse that was subjected to irradiation and treatment with [Sar 9 ,Met (O 2 ) n ]-substance P.
  • Substance P RKPQQFFGLM-NH 2 ; SEQ ID NO: 1 or a bioactive analog thereof such as Sar 9 ,Met( ⁇ 2 )' '-Substance P can be administered to stimulate wound healing.
  • the bioactive analog can be selected from the group consisting of [Met-OH n ]-substance P, [Met-OMe u ]-substance P, [Nle ⁇ ]-substance P, [Pro 9 ]-substance P, [Sar 9 ]-substance P, [Tyr 8 ] -substance P, Sar 9 , MeKO 2 ) 1 '-Substance P, and [p-Cl-Phe 7 ' 8] -substance P.
  • NK-I NK-I receptor
  • Compounds which have the same amino acid backbone as substance P can be routinely modified and tested for receptor agonist activity. Routine assays for such activities are known in the art and can be used.
  • the substance P or analog can be administered by any method known in the art, including via aerosol inhalation. Intravenous, topical, intratracheal, intrabronchial, intramuscular, sublingual, and oral administrations can also be used. Suitable dosages include 0.05 to 5 nanomolar substance P or analog for administration, or 0.1 to 2 nanomolar, or 0.5 to 1.5 nanomolar. For aerosol administration dosages include 0.05 to 5 micromolar substance P or analog, preferably 0.1 to 2 micromolar, and more preferably 0.5 to 1.5 micromolar. For direct intramuscular injection a 2 micromolar solution can be used, for example. Other useful concentration ranges of substance P or its bioactive analog in an aerosol administered is between 0.001 and 75 ⁇ M.
  • Concentrations for topical administration are in the range of 1 ⁇ M to 50 ⁇ M .
  • Amounts to be administered are typically between 1 ⁇ M and 10 ⁇ M.
  • Wounds which are amenable to treatment according to the present invention are those on the surface as well as internal to an animal body.
  • the wounds may be caused by accident, disease, or purposefully.
  • the wounds can, for example, be surgical wounds.
  • Amenable wounds include but are not limited to cutaneous wounds, muscular wounds, osseus lesions, gastrointestinal anastamoses, decubitus ulcers, gastrointestinal ulcers, and burn wounds.
  • the methods of the present invention can be applied to any mammal, including humans, horses, sheep, primates such as monkeys, apes, gibbons, chimpanzees, rodents such as mice, rats, guinea pigs, hamsters, ungulates such as cows.
  • Example 1 The male mice fought while confined with four mice/bin. They sustained extensive tail wounds from biting. We then exposed the mice to either 7, 8, or 9 Gy 60 Cobalt gamma radiation in a single acute dose.
  • [Sar ,Met(C>2) ]-substance P was administered by direct muscle injection in a 0.5 ml bolus at 2 micromolar concentration. Control animals received injections of normal saline. At 7 weeks post-radiation exposure, the control mice had unhealed tail wounds (see Fig. 1) while the [Sar 9 ,Met(O 2 )' ']-substance P -treated mice did not have any unhealed tail wounds (see Fig. 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2005/038646 2004-10-27 2005-10-25 Method to promote wound healing Ceased WO2006047625A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05813067A EP1809313A4 (en) 2004-10-27 2005-10-25 PROCESS FOR PROMOTING WOUND HEALING
AU2005299341A AU2005299341A1 (en) 2004-10-27 2005-10-25 Method to promote wound healing
US11/666,474 US20080318869A1 (en) 2004-10-27 2005-10-25 Method to Promote Wound Healing
JP2007539081A JP2008518020A (ja) 2004-10-27 2005-10-25 創傷治癒を促進する方法
CA002585265A CA2585265A1 (en) 2004-10-27 2005-10-25 Method to promote wound healing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62201504P 2004-10-27 2004-10-27
US60/622,015 2004-10-27

Publications (2)

Publication Number Publication Date
WO2006047625A2 true WO2006047625A2 (en) 2006-05-04
WO2006047625A3 WO2006047625A3 (en) 2006-07-27

Family

ID=36228442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/038646 Ceased WO2006047625A2 (en) 2004-10-27 2005-10-25 Method to promote wound healing

Country Status (6)

Country Link
US (1) US20080318869A1 (cg-RX-API-DMAC7.html)
EP (1) EP1809313A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008518020A (cg-RX-API-DMAC7.html)
AU (1) AU2005299341A1 (cg-RX-API-DMAC7.html)
CA (1) CA2585265A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006047625A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014016A1 (en) * 2016-07-15 2018-01-18 New Amsterdam Sciences Substance and method for treating radiation exposure
US10065031B2 (en) 2014-08-27 2018-09-04 Aleva Neurotherapeutics Deep brain stimulation lead

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101621149B1 (ko) 2014-07-09 2016-05-16 계명대학교 산학협력단 만성 창상용 동물 모델
KR101825041B1 (ko) * 2016-04-07 2018-02-02 주식회사 바이오솔루션 물질 p를 포함하는 상처치유용 약학 조성물
JP6901801B2 (ja) * 2017-06-14 2021-07-14 バイオソリューション カンパニー・リミテッドBio Solution Co Ltd 物質pを含むしわの改善または抗炎症化粧料組成物
KR102158969B1 (ko) * 2018-10-19 2020-09-23 주식회사 바이오솔루션 물질 p를 포함하는 난치성 궤양 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616562A (en) * 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation
JP4096115B2 (ja) * 2000-08-10 2008-06-04 輝夫 西田 皮膚創傷治癒促進剤
AU7776701A (en) * 2000-08-10 2002-02-25 Santen Pharmaceutical Co Ltd Skin wound healing promoters
US20060153789A1 (en) * 2002-12-18 2006-07-13 Witten Mark L Stimulation of hair regrowth
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1809313A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10065031B2 (en) 2014-08-27 2018-09-04 Aleva Neurotherapeutics Deep brain stimulation lead
WO2018014016A1 (en) * 2016-07-15 2018-01-18 New Amsterdam Sciences Substance and method for treating radiation exposure

Also Published As

Publication number Publication date
EP1809313A4 (en) 2008-01-23
AU2005299341A1 (en) 2006-05-04
WO2006047625A3 (en) 2006-07-27
EP1809313A2 (en) 2007-07-25
CA2585265A1 (en) 2006-05-04
US20080318869A1 (en) 2008-12-25
JP2008518020A (ja) 2008-05-29

Similar Documents

Publication Publication Date Title
DE69909794T2 (de) Verwendung eines dipeptids für wiederherstellungsprozesse
Mirski et al. Interruption of the connections of the mammillary bodies protects against generalized pentylenetetrazol seizures in guinea pigs
Adamec et al. Amygdala kindling, anxiety, and corticotrophin releasing factor (CRF)
Straube et al. Studies with cysteinamine and cysteine in x-irradiated animals
Brandao et al. Effects of morphine and midazolam on reactivity to peripheral noxious and central aversive stimuli
US20080318869A1 (en) Method to Promote Wound Healing
JP5823486B2 (ja) 放射線および熱の複合損傷の治療方法
Hope et al. Release of immunoreactive galanin in the spinal cord of rats with ankle inflammation: studies with antibody microprobes
JPS63500799A (ja) 持続性オピオイド拮抗作用を得るための方法および組成物
US20230270739A1 (en) Methods and Compositions for Treating Pain While Minimizing the Risk of Opioid Addiction
Mazarati et al. Felbamate in experimental model of status epilepticus
Miyachi et al. Low-dose X-ray-induced depression of sexual behavior in mice
Renecker et al. Antagonism of xylazine hydrochloride with yohimbine hydrochloride and 4-aminopyridine in captive wapiti
AU2445900A (en) Regulation of anaesthesia
Stefko et al. Experimental investigation of nine antitussive drugs
McGIVERN et al. Effect of naloxone and housing conditions on shock-elicited reflexive fighting: Influence of immediate prior stress
RU2061475C1 (ru) Лекарственное средство, стимулирующее эритроидный росток кроветворения при цитостатических миелодепрессиях
Davis Toe and muscle injuries of the racing greyhound
RU2083207C1 (ru) Способ лечения экспериментального сапа у золотистых хомячков
EP4506012A1 (en) Use of extracts from rabbit skin inflamed by vaccinia virus in treatment of alzheimer's disease
RU2063751C1 (ru) Лекарственное средство, стимулирующее гранулоцитарный росток кроветворения при цитостатической гипоплазии костного мозга
CN109701003A (zh) 一种北极熊用复方注射剂及其制备方法
Nakajima Attenuation of amnesia by hydrocortisone in the mouse
Baxter et al. Blood histamine levels in swine following total body x-radiation and a flash burn
RU2061492C1 (ru) Противовоспалительное средство для лечения ретикулоперитонитов крупного рогатого скота

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005299341

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2585265

Country of ref document: CA

Ref document number: 2007539081

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005813067

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005299341

Country of ref document: AU

Date of ref document: 20051025

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005813067

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11666474

Country of ref document: US